Have £1,000 to invest in September? Here are two stunning growth stocks to consider

Roland Head considers the outlook for two of the AIM market’s most successful growth stocks.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today, I’m looking at two highly successful growth stocks listed on London’s AIM market. Both companies have delivered share price gains of more than 80% since June 2014, massively outperforming the FTSE 100’s 8% gain over the same period. Can this market-beating performance be maintained as we head into 2019?

Ahead of expectations

Internet marketing group Taptica International (LSE: TAP) counts big-cap names such as GlaxoSmithKline and Starbucks among its clients. The group’s focus is on delivering data-driven advertising through mobile, video, and social media channels.

Taptica shares have fallen by about 25% so far this year, due to concerns that growth could slow. Today’s half-year results suggest to me that this price drop may have created a buying opportunity.

Revenue rose by 119% to $144m during the six months to 30 June, while operating profit climbed 34% to $13.9m. Profits for the full year are now expected to be ahead of previous expectations, according to management.

Based on analysts’ consensus forecasts, I now expect adjusted earnings per share to rise by more than 10% this year. Forecast for 2019 suggest a similar increase.

Too cheap to ignore?

One risk is that Taptica might start paying too much for acquisitions in pursuit of growth. A good way to measure this is with return on capital employed (ROCE), which compares operating profit with capital invested in a business.

The group’s ROCE was a healthy 17.4% in 2017 and has fallen to 16.7% over the 12 months to 30 June. I’m comfortable with this, given that the group is continuing to invest in its fast-growing Asian operations.

At the last-seen share price of 375p, this growth stock trades on a forecast P/E of about 11, with a dividend yield of 1.6%. That looks good value to me.

AIM’s biggest and best?

The biggest company on AIM is online fashion retailer ASOS (LSE: ASC), with a market-cap of £5.1bn.

The ASOS share price has risen by a staggering 25,400% since the firm listed in October 2001. Over the same period, the AIM All-Share Index has risen by just 32%, while the FTSE 100 has gained 44%.

This success shows how picking winning stocks (and sticking with them) can deliver life-changing gains. A £1,000 investment in ASOS in 2001 would be worth about £250,000 today.

Can ASOS keep rising?

ASOS currently trades on a 2018 forecast price/earnings ratio of 64, falling to a P/E of 52 for 2019. That’s a demanding valuation, as my colleague Rupert Hargreaves recently noted.

Analysts’ profit forecasts indicate that earnings per share were expected to rise by about 25% during the year ending 31 August. Earnings growth for the current year is expected to be about 22%.

These are impressive figures, if they can be maintained. ASOS’s track record suggests that this may be possible. During the first half of last year, the number of active customers rose by 17%, while total orders climbed 28% to 29.9m.

Some of this growth is coming from the group’s international expansion. At the moment, sales to the US and EU countries are still both lower than UK sales. This suggests there’s still plenty of opportunity for growth, despite increasing levels of competition from rivals such as Boohoo.com.

However, a premium valuation and a competitive marketplace means there’s a significant risk of disappointment. Because of this, I believe it makes sense to wait for the next market dip before considering a new investment in ASOS.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended ASOS, GlaxoSmithKline, and Starbucks. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Market Movers

Up 11% today, can this FTSE 250 stock finally get motoring?

Jon Smith explains why the Aston Martin share price has jumped this morning, but urges caution after he picks apart…

Read more »

Investing Articles

With £456m of net cash, FTSE 100 stock easyJet’s ready for take-off

Our writer's been positive on this FTSE 100 for some time, but these Q3 results and its growing cash pile…

Read more »

A senior woman sits up on the exam table at a doctors appointment. She is dressed casually in a blue sweater and has a smile on her face as she glances at the doctor. Her female doctor is wearing a white lab coat and seated in front of her as she takes notes on a tablet.
Investing Articles

Primary Health Properties: a FTSE 250 REIT with a 6% yield, a growing dividend, and a positive outlook

After its latest results show rental income growth, Stephen Wright's looking to buy a FTSE 250 REIT set to benefit…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

How much passive income could I make for every £1,000 invested in Aviva shares?

Even a relatively small investment in Aviva shares could generate much greater passive income, particularly if the dividends are reinvested…

Read more »

Close-up of British bank notes
Investing Articles

I’m considering 100 shares in this FTSE 250 gem to aim for £300 a month in dividends

Mark Hartley outlines why a lesser-known banking stock from the FTSE 250's worth considering for an income portfolio in 2024.

Read more »

Investing Articles

History suggests these UK shares might soar if interest rates are cut in August

Some UK shares could rocket if interest rates fall from its 5.25% high next month. And there's one our writer…

Read more »

Female Doctor In White Coat Having Meeting With Woman Patient In Office
Investing Articles

Here’s why H1 results could boost the AstraZeneca share price

The AstraZeneca share price has been a success story in the past five years. With H1 results due, can it…

Read more »

Investing Articles

£17,365 in savings? Here’s how I’d use it to target a £6,700-a-month passive income

Here's how a lump sum investment could pave the way for me to make a four-figure monthly passive income in…

Read more »